Placental MSC benefit typically persists for 12–36 months; some patients maintain improvement longer, while others experience gradual recurrence. HSCT-induced remissions have been sustained for 5+ years in published series, though late relapse is possible. Neither therapy cures scleroderma; disease remission appears to be achieved, not cure.
Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins. The underlying immunological dysfunction involves autoreactive T cells, B cells producing pathogenic antibodies (anti-topoisomerase, anti-centromere), and dysregulated cytokine signalling (TGF-β, IL-6). Placental MSCs are being explored as an anti-inflammatory and immunomodulatory intervention, delivering cytokines and cell-surface molecules that suppress autoreactive immune cells and potentially reprogram fibroblast behaviour. Unlike conventional disease-modifying antirheumatic drugs (DMARDs), cell therapy aims to reset immune tolerance rather than merely suppress inflammation. Note: autologous haematopoietic stem-cell transplantation (HSCT) is an established, though intensive, option for severe early-stage systemic sclerosis in selected candidates, with demonstrated benefit in some clinical series.
Am I a candidate? → · Scleroderma (Systemic Sclerosis): full overview → · Scleroderma (Systemic Sclerosis) cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية